BCDA
Revolutionizing Heart Failure Treatment: BioCardia's Groundbreaking Q4 2025 Results
BioCardia, a leader in cardiovascular disease treatment, recently reported its Q4 2025 results, marking a significant milestone in the company's mission to develop and enhance therapies for this debilitating condition. The key highlight of the quarter is the outstanding performance of the company's CardiAMP autologous minimally